Microglia, the resident immune cells of the central nervous system, play a crucial role in maintaining brain homeostasis. However, their dysregulation is a hallmark of neurodegenerative diseases. In Alzheimer’s disease, microglia can exhibit a pro-inflammatory M1 phenotype, which has been associated with increased neuroinflammation and consequent neuronal damage. The study by Wang et al. investigates how miR-199a-3p contributes to this pathogenic process by promoting or exacerbating M1 polarization of microglia.

The background of this research is rooted in the increasing recognition of the importance of non-coding RNAs, particularly microRNAs, in regulating gene expression and cellular processes. MicroRNAs are short, single-stranded RNA molecules that can modulate mRNA stability and translation. Dysregulation of specific microRNAs has been implicated in various diseases, including cancer and neurodegenerative disorders. In the context of Alzheimer’s disease, this regulatory aspect takes on heightened relevance as it might reveal novel therapeutic targets.

The study utilized a transgenic mouse model that expresses specific mutations in genes associated with familial Alzheimer’s disease. Researchers observed that these mice exhibited typical hallmarks of Alzheimer’s, including amyloid-beta plaque accumulation and neuroinflammation. Investigating the role of miR-199a-3p, they employed various techniques, including brain tissue analysis and flow cytometry, to examine microglial behavior and gene expression changes.

One of the significant findings of the research is the upregulation of miR-199a-3p in the brains of Alzheimer’s model mice. This increase correlated with enhanced levels of pro-inflammatory cytokines, suggesting a direct link between miR-199a-3p expression and neuroinflammatory processes. When the researchers explored the effect of inhibiting miR-199a-3p, they discovered a downregulation of M1 markers in microglia, indicating that this microRNA plays a pivotal role in promoting the pro-inflammatory state characteristic of Alzheimer’s pathology.

Further analysis revealed that miR-199a-3p targets specific messenger RNAs that encode proteins involved in anti-inflammatory signaling pathways. By downregulating these targets, miR-199a-3p effectively shifts the balance toward M1 polarization, instigating a cascade of inflammatory responses. This mechanism reinforces the idea that targeting microRNAs could be a promising therapeutic approach to mitigate neuroinflammation in Alzheimer’s disease.

The implications of these findings are profound. They suggest that therapies aimed at modulating miR-199a-3p levels could potentially reverse or alleviate neuroinflammatory conditions associated with Alzheimer’s disease. While pharmaceutical interventions are currently limited in their effectiveness against this devastating condition, the targeting of microRNAs offers a new horizon for therapeutic strategies.

Moreover, the study emphasizes the importance of understanding the multifactorial nature of Alzheimer’s disease pathology. Neuroinflammation does not act in isolation; it interacts with other molecular pathways, including amyloid-beta toxicity and tau pathology. The intricate interplay between these processes necessitates a comprehensive approach to treatment that considers the multifaceted underpinnings of the disease.

As the field moves forward, more research is needed to dissect the specific pathways through which miR-199a-3p mediates its effects on microglial polarization and neuroinflammation. Additionally, it will be crucial to explore how other microRNAs may contribute or counteract the effects of miR-199a-3p, providing a broader understanding of microRNA networks in the brain during Alzheimer’s disease.

In conclusion, the work of Wang and colleagues underpins a growing body of evidence demonstrating the critical roles that microRNAs play in neurodegenerative processes. Their findings not only enhance our understanding of the molecular mechanisms driving Alzheimer’s disease but also lay the groundwork for future innovations in therapeutics aimed at neuroinflammation. As researchers continue to unravel the complex tapestry of Alzheimer’s disease pathology, the potential for transformative treatments based on microRNA modulation becomes increasingly tangible.

In summary, the paper presents a compelling case for the involvement of miR-199a-3p in exacerbating neuroinflammation through M1 microglial polarization in Alzheimer’s disease models. This research not only enriches the scientific discourse surrounding Alzheimer’s but also serves as a clarion call for further investigations into the therapeutic potential of microRNA-based strategies.

Subject of Research: The role of MicroRNA-199a-3p in neuroinflammation and microglial polarization in Alzheimer’s disease.

Article Title: Publisher Correction: Mir-199a-3p aggravates neuroinflammation in an Alzheimer’s disease transgenic mouse model by promoting M1-polarization microglia.

Article References:

Wang, C., Bu, X., Cao, M. et al. Publisher Correction: Mir-199a-3p aggravates neuroinflammation in an Alzheimer’s disease transgenic mouse model by promoting M1-polarization microglia.
BMC Neurosci 26, 58 (2025). https://doi.org/10.1186/s12868-025-00974-4

Image Credits: AI Generated

DOI: 10.1186/s12868-025-00974-4

Keywords: Alzheimer’s disease, microRNA-199a-3p, neuroinflammation, microglia, M1 polarization, transgenic mouse model.

Alzheimer’s disease (AD) has long been associated with the APOE gene, which exists in three major isoforms: APOE2, APOE3, and APOE4. Among these, APOE4 is recognized as a major genetic risk factor for late-onset AD, whereas APOE2 appears to confer protective effects. Previous research has firmly established that APOE genotype influences amyloid plaque deposition, a pathological hallmark of AD. However, whether switching from APOE4 to APOE2 within specific brain cell types late in disease progression could ameliorate pathology and cognitive deficits remained largely unexplored until now.

The research team employed a sophisticated genetic engineering approach to specifically replace APOE4 with APOE2 exclusively in astrocytes—the star-shaped glial cells known to regulate neuronal support and amyloid metabolism. By crossing APOE4s2^A mice with the 5xFAD transgenic mouse model, which rapidly develops AD-related amyloid pathology, and administering tamoxifen to induce the allelic switch at 6 months of age, the scientists created a system to investigate late-stage therapeutic gene replacement.

Two months after inducing the APOE4 to APOE2 allelic switch within astrocytes, mice underwent a battery of cognitive tests, including associative fear conditioning and the Morris water maze. The results revealed a striking improvement in associative learning and memory, particularly in female mice, while spatial memory as assessed by the water maze test showed no significant changes. This dissociation suggests that astrocytic APOE genotype influences certain cognitive domains more robustly than others.

Critically, histopathological analysis of the brain tissues demonstrated that the astrocyte-specific APOE switch substantially lowered amyloid plaque load compared to controls. Quantitative immunohistochemistry revealed a pronounced decrease in total amyloid-positive areas in the brain, indicating that even after pathology has been established, astrocytic APOE2 expression can slow or delay further amyloid accumulation. Remarkably, this effect was regionally widespread, with significant plaque reductions observed in the hippocampus, olfactory area, and thalamus—regions heavily implicated in cognitive functions disrupted in AD.

To rigorously quantify amyloid pathology, enzyme-linked immunosorbent assays (ELISA) measured soluble and insoluble forms of Aβ40 and Aβ42 peptides from whole brain homogenates. The introduction of APOE2 specifically in astrocytes resulted in significant reductions in both soluble and insoluble amyloid beta isoforms, underscoring a comprehensive attenuation of amyloid pathology at a molecular level. These findings align well with the known roles of astrocytes in amyloid clearance and homeostasis.

Interestingly, the study found minimal sex differences in pathological outcomes, except for slightly higher baseline amyloid burdens in female control mice. The reduction in plaque load post-switch was consistent across sexes, implying that astrocyte-targeted APOE alterations have robust therapeutic potential irrespective of gender. While some subtle sex-dependent effects were noted in synaptic markers distal to plaques, overall synaptic integrity was preserved following APOE switching.

In considering other cerebrovascular impacts, the team evaluated cerebral amyloid angiopathy (CAA), another APOE4-associated pathology characterized by amyloid deposits in brain vasculature. Surprisingly, astrocyte-specific conversion to APOE2 did not significantly alter CAA burden. This suggests that while parenchymal amyloid plaques are strongly modulated by astrocytic APOE genotype, vascular amyloid deposition may be regulated by additional or alternative mechanisms, potentially involving other cell types or systemic factors.

Additionally, the expression of ZO1, a tight junction protein critical for maintaining blood-brain barrier integrity, remained unchanged after the allelic switch, indicating that the intervention did not compromise vascular barrier properties. This highlights the specificity and safety profile of the astrocytic gene conversion strategy, which does not appear to induce detrimental vascular side effects.

Collectively, the findings of this study offer compelling evidence that a targeted, late-stage allelic switch from APOE4 to APOE2 in astrocytes can alleviate key pathological and cognitive features of AD in a mouse model. By effectively reducing amyloid plaque burden and improving associative memory, this approach stands out as a promising avenue for therapeutic development that might be translatable into human interventions.